Abstract:What's new? Anti‐HER2 agents are associated with occurrences of blurred vision, conjunctivitis, and other adverse effects on the eyes. Such ocular adverse events, however, are often underestimated and lack comprehensive evaluation. Here, using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), the authors conducted a retrospective investigation of ocular toxicity risk linked to anti‐HER2 agents. Analyses reveal varying degrees of association between ocular toxicity and anti‐HER2 drugs. Notably, risk was significantly elevated in association with antibody drugs compared to tyrosine kinase inhibitors. Furthermore, several ocular toxicity signals were identified that currently are absent from product labels. Anti‐human epidermal growth factor receptor 2 (HER2) agents have exhibited pronounced tumor‐inhibitory activity, yet the accompanying ocular toxicity has frequently been underestimated. We aim to conduct a comprehensive comparative analysis of ocular toxicity risk related to various anti‐HER2 agents. We executed a retrospective pharmacovigilance investigation based on the FDA Adverse Event Reporting System (FAERS) database, covering the period from Q2 2018 to Q1 2023. The disproportionality analysis was performed to assess ocular toxicity risk. Multivariate logistic regression was implemented to mitigate potential biases. Moreover, the time to onset of ocular toxicity was also evaluated. A total of 3467 ocular adverse event (AE) reports concerning anti‐HER2 agents were collected. At the preferred term (PT) level, there were 69 positive signals, among which excessive eye blinking, abnormal sensation in the eye, and asthenopia presented a significant risk. In comparison to tyrosine kinase inhibitors (TKIs), antibody drugs were associated with a broader range of ocular disorders at Standardized MedDRA Queries (SMQ)levels, including conjunctival disorders, corneal disorders, ocular infections, ocular motility disorders, optic nerve disorders, and retinal disorders. In terms of onset time, pertuzumab displayed an earlier onset at 21.5 days, while trastuzumab deruxtecan had the latest at 91.5 days. In summary, our study reveals varying degrees of ocular toxicity related to anti‐HER2 agents, with a significantly higher risk observed in antibody drugs. Additionally, novel ocular toxicity signals, not documented in product labels, have been detected. In the future, further research will be necessary to validate our findings.

Dry eye disease adverse reaction of pharmacological treatment for early-stage breast cancer

Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study

[Ocular surface adverse reactions of antitumor-targeted drugs]

Focusing on systematic therapy of dry eye

Real-World Large Sample Assessment of Drug-related Dry Eye Risk: Based on the FDA Adverse Event Reporting System Database

Ocular Surface Side Effects of Novel Anticancer Drugs

The Significance of the Ocular Adverse Effect Induced by Systemic Taxane Application

Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report

Dry Eye Management: Targeting the Ocular Surface Microenvironment

Analyses of Ocular Adverse Reactions Associated With Anticancer Drugs Based on the Japanese Pharmacovigilance Database

Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China

Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies

Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review

Natural products and derivatives for breast cancer treatment: From drug discovery to molecular mechanism

Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience

Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients: a comprehensive analysis using speckle tracking echocardiography

Recent progress of nanomedicine in managing dry eye disease

Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage

Eye metastasis in breast cancer: case report and review of literature

Ocular and Periocular Metastasis in Breast Cancer: Clinical Characteristics, Prognostic Factors and Treatment Outcome